Michael Dudley

548 total citations
26 papers, 431 citations indexed

About

Michael Dudley is a scholar working on Pharmacology, Molecular Medicine and Infectious Diseases. According to data from OpenAlex, Michael Dudley has authored 26 papers receiving a total of 431 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pharmacology, 14 papers in Molecular Medicine and 6 papers in Infectious Diseases. Recurrent topics in Michael Dudley's work include Antibiotics Pharmacokinetics and Efficacy (17 papers), Antibiotic Resistance in Bacteria (14 papers) and Antibiotic Use and Resistance (6 papers). Michael Dudley is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (17 papers), Antibiotic Resistance in Bacteria (14 papers) and Antibiotic Use and Resistance (6 papers). Michael Dudley collaborates with scholars based in United States, Switzerland and Austria. Michael Dudley's co-authors include Olga Lomovskaya, Debora Rubio-Aparicio, Dongxu Sun, Ruslan Tsivkovski, Kirk Nelson, Maxim Totrov, Robert M. Swift, Paolo B. DePetrillo, Jeffery S. Loutit and David Sanders and has published in prestigious journals such as Scientific Reports, The American Journal of Medicine and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Michael Dudley

24 papers receiving 404 citations

Peers

Countries citing papers authored by Michael Dudley

Since Specialization

Citations

This map shows the geographic impact of Michael Dudley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Dudley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Dudley more than expected).

Fields of papers citing papers by Michael Dudley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Dudley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Dudley. The network helps show where Michael Dudley may publish in the future.

Co-authorship network of co-authors of Michael Dudley

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Dudley. A scholar is included among the top collaborators of Michael Dudley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Dudley. Michael Dudley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Communicable Episode 10: Pipeline update on new antibiotics & other antimicrobials		Markus Zeitlinger, Michael Dudley et al.	0
2	In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales	Antimicrobial Agents and Chemotherapy	Olga Lomovskaya, Mariana Castanheira et al.	30
3	New boronate drugs and evolving NDM-mediated beta-lactam resistance	Antimicrobial Agents and Chemotherapy	Olga Lomovskaya, Ruslan Tsivkovski et al.	14
4	QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics	Frontiers in Microbiology	Olga Lomovskaya, Ruslan Tsivkovski et al.	34
5	The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant Enterobacterales	Antimicrobial Agents and Chemotherapy	Olga Lomovskaya, Debora Rubio-Aparicio et al.	18
6	In Vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa	Antimicrobial Agents and Chemotherapy	Olga Lomovskaya, Debora Rubio-Aparicio et al.	21
7	In Vitro Activity of the Ultrabroad-Spectrum-Beta-Lactamase Inhibitor QPX7728 against Carbapenem-Resistant Enterobacterales with Varying Intrinsic and Acquired Resistance Mechanisms	Antimicrobial Agents and Chemotherapy	Kirk Nelson, Debora Rubio-Aparicio et al.	37
8	A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program	Open Forum Infectious Diseases	Greg Moeck, Christopher Lucasti et al.	16
9	1181. Use of the Combination Antibiogram in the Era of MDR Gram-Negative Pathogens	Open Forum Infectious Diseases	Kenneth Klinker, Kartikeya Cherabuddi et al.	0
10	Therapy targeted to the metastatic niche is effective in a model of stage IV breast cancer	Scientific Reports	Byunghee Yoo, Amol Kavishwar et al.	37
11	Potency of Meropenem-Vaborbactam in Lung Surfactant	Antimicrobial Agents and Chemotherapy	Debora Rubio-Aparicio, Michael Dudley et al.	6
12	In Vitro Assessment of Combined Polymyxin B and Minocycline Therapy against Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae	Antimicrobial Agents and Chemotherapy	Dennis S. Huang, Rajnikant Sharma et al.	17
13	Rationale for Dose Selection for Carbavance ([CVC] Meropenem/RPX7009) in Phase 3 Trials	Open Forum Infectious Diseases	Olga Lomovskaya, David C. Griffith et al.	4
14	Neutralization ofClostridium difficiletoxin A using antibody combinations	mAbs	Stephen J. Demarest, Mangala J. Hariharan et al.	28
15	Diastolic Dysfunction, Cardiovascular Aging, and the Anesthesiologist	Anesthesiology Clinics	David Sanders, Michael Dudley et al.	25
16	Resistance Surveillance, Pharmacokinetics/Pharmacodynamics, and Simulation: Can the Use of Old Tools Be Improved to Impact Antibiotic Resistance?		Michael Dudley	1
17	Relationships between structure, antibacterial activity, serum stability, pharmacokinetics and efficacy in 3-(heteroarylthio)cephems. Discovery of RWJ-333441 (MC-04,546)	Bioorganic & Medicinal Chemistry	Tomasz Glinka, Keith Huie et al.	7
18	Bacterial Resistance Mechanisms to β‐Lactam Antibiotics: Assessment of Management Strategies	Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	Michael Dudley	3
19	Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation	Journal of Antimicrobial Chemotherapy	Claudio Viscoli, Michael Dudley et al.	33
20	Corneal Lesions Produced in Rabbits by an Extract of Fusarium Moniliforme	Archives of Ophthalmology	Michael Dudley, Ernest W. Chick	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact